Tag: patient perspective
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.